secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioStem Technologies, Inc. (BSEM)
CIK:        0001658678
Form:       8-K
Filed at:   2026-08-07T20:15:17+00:00
Accession:  0001193125-26-340271
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioStem Technologies approved for Nasdaq Capital Market listing; trading starts Aug 7
--------------------------------------------------------------------------------

- Nasdaq approved BSEM common stock for listing on The Nasdaq Capital Market on Aug 6, 2026.
- Trading transitions from OTCQB to Nasdaq effective at market open on Aug 7, 2026; ticker remains BSEM.
- No shareholder action required; CEO Jason Matuszewski cites expanded capital access and liquidity.
- Company is a regenerative medicine firm focused on perinatal tissue allograft products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658678/000119312526340271/0001193125-26-340271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658678/000119312526340271/bsem-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-340271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer